Efficacy of combined targeted therapy with PI3K and CDK4/6 or PARP and WEE1 inhibitors in neuroblastoma cell lines

Lukoseviciute,Monika; Holzhauser,Stefan; Pappa,Eleni; Mandal,Tamoghna; Dalianis,Tina; Kostopoulou,Ourania N.

doi:10.3892/or.2023.8603

Efficacy of combined targeted therapy with PI3K and CDK4/6 or PARP and WEE1 inhibitors in neuroblastoma cell lines

Authors:
- Monika Lukoseviciute
- Stefan Holzhauser
- Eleni Pappa
- Tamoghna Mandal
- Tina Dalianis
- Ourania N. Kostopoulou
View Affiliations

Affiliations: Department of Oncology‑Pathology, Karolinska Institute, 17164 Stockholm, Sweden
Published online on: July 19, 2023 https://doi.org/10.3892/or.2023.8603
Article Number: 166
Copyright: © Lukoseviciute et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neuroblastoma (NB), the most frequent solid extracranial tumor in children, is not always cured by current aggressive therapies that have notable adverse effects; therefore, novel treatments are necessary. Phosphoinositide 3‑kinase (PI3K) and fibroblast growth factor receptor inhibitors exhibit synergistic effect in NB cell lines. In the present study, mono‑ and combination therapy of the United States Food and Drug Administration‑approved PI3K, cyclin‑dependent kinase‑4/6 (CDK4/6), poly‑ADP‑ribose‑polymerase (PARP) and WEE1 G2 checkpoint kinase (WEE1) inhibitors (BYL719, PD‑0332991, BMN673 and MK‑1775, respectively), were used to treat NB cell lines SK‑N‑AS, SK‑N‑BE(2)‑C, SK‑N‑DZ, SK‑N‑FI and SK‑N‑SH and viability (assessed by WST‑1 assay), proliferation (incucyte analysis) and cell cycle (FACS) changes were assessed. Treatments with all single drugs presented dose‑dependent responses with decreased viability and proliferation and combining BYL719 with PD‑0332991 or BMN673 with MK‑1775 resulted in additive or synergistic effects in most cell lines., except for SK‑N‑SH for the former and for SK‑N‑AS for the latter. Moreover, combining MK‑1775 and BMN673 decreased the numbers of cells in S phase to a greater extent than either drug alone, while when combining PD‑0332991 and BYL719 the observed effect was close to that of PD‑0332991 alone. To summarize, PI3K and CDK4/6 or PARP and WEE1 exhibited synergistic anti‑NB effects and lower doses of the inhibitors could be utilized, thereby potentially reducing adverse side effects.

View Figures

View References

1	Ward E, DeSantis C, Robbins A, Kohler B and Jemal A: Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 64:83–103. 2014. View Article : Google Scholar : PubMed/NCBI
2	D'Angio GJ, Evans AE and Koop CE: Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet. 1:1046–1049. 1971. View Article : Google Scholar : PubMed/NCBI
3	Nakagawara A, Li Y, Izumi H, Muramori K, Inada H and Nishi M: Neuroblastoma. Jpn J Clin Oncol. 1:214–241. 2018. View Article : Google Scholar
4	Bo Q and Matthay KK: Advancing therapy for neuroblastoma. Nat Rev Clin Oncol. 19:515–533. 2022. View Article : Google Scholar : PubMed/NCBI
5	Hero B, Simon T, Spitz R, Ernestus K, Gnekow AK, Scheel-Walter HG, Schwabe D, Schilling FH, Benz-Bohm G and Berthold F: Localized infant neuroblastomas often show spontaneous regression: Results of the prospective trials NB95-S and NB97. J Clin Oncol. 26:1504–1510. 2008. View Article : Google Scholar : PubMed/NCBI
6	Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L and Weiss WA: Neuroblastoma. Nat Rev Dis Prim. 2:160782016. View Article : Google Scholar : PubMed/NCBI
7	London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, Naranjo A and Park JR: Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on children's oncology group early-phase trials. Cancer. 123:4914–4923. 2017. View Article : Google Scholar : PubMed/NCBI
8	Johnsen JI, Dyberg C and Wickström M: Neuroblastoma-A neural crest derived embryonal malignancy. Front Mol Neurosci. 12:92019. View Article : Google Scholar : PubMed/NCBI
9	Hemmings BA and Restuccia DF: The PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol. 7:a0266092015. View Article : Google Scholar : PubMed/NCBI
10	Kostopoulou ON, Holzhauser S, Lange BKA, Ohmayer A, Andonova T, Bersani C, Wickström M and Dalianis T: Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines. Int J Oncol. 55:1372–1384. 2019.PubMed/NCBI
11	Holzhauser S, Lukoseviciute M, Andonova T, Ursu RG, Dalianis T, Wickström M and Kostopoulou ON: Targeting fibroblast growth factor receptor (FGFR) and Phosphoinositide 3-kinase (PI3K) signaling pathways in medulloblastoma cell lines. Anticancer Res. 40:53–66. 2020. View Article : Google Scholar : PubMed/NCBI
12	Holzhauser S, Lukoseviciute M, Papachristofi C, Vasilopoulou C, Herold N, Wickström M, Kostopoulou ON and Dalianis T: Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines. Int J Oncol. 58:211–225. 2021. View Article : Google Scholar : PubMed/NCBI
13	Lukoseviciute M, Maier H, Poulou-Sidiropoulou E, Rosendahl E, Holzhauser S, Dalianis T and Kostopoulou ON: Targeting PI3K, FGFR, CDK4/6 signaling pathways together with cytostatics and radiotherapy in two medulloblastoma cell lines. Front Oncol. 11:7486572021. View Article : Google Scholar : PubMed/NCBI
14	Katso R, Okkenhaug K, Ahmadi K, White S, Timms J and Waterfield MD: Cellular function of phosphoinositide 3-kinases: Implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 17:615–675. 2001. View Article : Google Scholar : PubMed/NCBI
15	Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
16	King D, Yeomanson D and Bryant HE: PI3King the lock: Targeting the PI3K/Akt/mTOR pathway as a novel therapeutic strategy in neuroblastoma. J Pediatr Hematol Oncol. 37:245–251. 2015. View Article : Google Scholar : PubMed/NCBI
17	Khezri MR, Jafari R, Yousefi K and Zolbanin NM: The PI3K/AKT signaling pathway in cancer: Molecular mechanisms and possible therapeutic interventions. Exp Mol Pathol. 127:1047872022. View Article : Google Scholar : PubMed/NCBI
18	Zage PE: Novel therapies for relapsed and refractory neuroblastoma. Children (Basel). 5:1482018.PubMed/NCBI
19	Creevey L, Ryan J, Harvey H, Bray IM, Meehan M, Khan AR and Stallings RL: MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1. Mol Cancer. 12:232013. View Article : Google Scholar : PubMed/NCBI
20	Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, Li Y, Carpenter EL, Attiyeh EF, Diskin SJ, et al: Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 19:6173–6182. 2013. View Article : Google Scholar : PubMed/NCBI
21	Knudsen ES, Pruitt SC, Hershberger PA, Witkiewicz AK and Goodrich DW: Cell cycle and beyond: Exploiting new RB1 controlled mechanisms for cancer therapy. Trends Cancer. 5:308–324. 2019. View Article : Google Scholar : PubMed/NCBI
22	Morgan DO: Cyclin-dependent kinases: Engines, clocks, and microprocessors. Annu Rev Cell Dev Biol. 13:261–291. 1997. View Article : Google Scholar : PubMed/NCBI
23	Sherr CJ and Roberts JM: Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 18:2699–2711. 2004. View Article : Google Scholar : PubMed/NCBI
24	Hamilton E and Infante JR: Targeting CDK4/6 in patients with cancer. Cancer Treat Rev. 45:129–138. 2016. View Article : Google Scholar : PubMed/NCBI
25	Ortega S, Malumbres M and Barbacid M: Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta. 1602:73–87. 2022.PubMed/NCBI
26	Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW and Jager A: Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: Similarities and differences. Drugs. 81:317–331. 2021. View Article : Google Scholar : PubMed/NCBI
27	Schmidt EE, Ichimura K, Reifenberger G and Collins VP: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 15:6321–6324. 1994.PubMed/NCBI
28	Muranen T, Meric-Bernstam F and Mills GB: Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors. Cancer Cell. 26:7–9. 2014. View Article : Google Scholar : PubMed/NCBI
29	Bonelli MA, Digiacomo G, Fumarola C, Alfieri R, Quaini F, Falco A, Madeddu D, Monica SL, Cretella D, Ravelli A, et al: Combined inhibition of CDK4/6 and PI3K/AKT/mTOR pathways induces a synergistic anti-tumor effect in malignant pleural mesothelioma cells. Neoplasia. 19:637–648. 2017. View Article : Google Scholar : PubMed/NCBI
30	Loibl S and Furlanetto J: Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer. Breast. 62:S70–S79. 2022. View Article : Google Scholar : PubMed/NCBI
31	Vora SR, Juric D, Kim N, Mino-Kenudson M, Huynh T, Costa C, Lockerman EL, Pollack SF, Liu M, Li X, et al: CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell. 26:136–149. 2014. View Article : Google Scholar : PubMed/NCBI
32	Paik J: Olaparib: A review as first-line maintenance therapy in advanced ovarian cancer. Target Oncol. 16:847–856. 2021. View Article : Google Scholar : PubMed/NCBI
33	Brown TJ and Reiss KA: PARP inhibitors in pancreatic cancer. Cancer J. 27:465–475. 2021. View Article : Google Scholar : PubMed/NCBI
34	De Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, et al: Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 382:2091–2102. 2022. View Article : Google Scholar
35	Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, et al: Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 22:1721–1731. 2021. View Article : Google Scholar : PubMed/NCBI
36	Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, Ju Z, Vellano CP, Lu Y, LI Y, et al: Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy. Cancer Cell. 35:851–867.e857. 2019. View Article : Google Scholar : PubMed/NCBI
37	di Rorà AG, Cerchione C, Martinelli G and Simonetti G: A WEE1 family business: Regulation of mitosis, cancer progression, and therapeutic target. J Hematol Oncol. 13:1262020. View Article : Google Scholar : PubMed/NCBI
38	Foucquier J and Guedj M: Analysis of drug combinations: Current methodological landscape. Pharmacol Res Perspect. 3:e001492015. View Article : Google Scholar : PubMed/NCBI
39	Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
40	Kostopoulou ON, Zupancic M, Pont M, Papin E, Lukoseviciute M, Mikelarena BA, Holzhauser S and Dalianis T: Targeted therapy of HPV positive and negative tonsillar squamous cell carcinoma cell lines reveals synergy between CDK4/6, PI3K and sometimes FGFR inhibitors, but rarely between PARP and WEE1 inhibitors. Viruses. 14:13722022. View Article : Google Scholar : PubMed/NCBI
41	Agostinetto E, Debien V, Marta GN, Lambertini M, Piccart-Gebhart M and de Azambuja E: CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer. Eur J Clin Invest. 51:e135352021. View Article : Google Scholar : PubMed/NCBI
42	Holzhauser S, Wild N, Zupancic M, Ursu RG, Bersani C, Näsman A, Kostopoulou Ourania N and Dalianis T: Targeted therapy with PI3K and FGFR inhibitors on human papillomavirus positive and negative tonsillar and base of tongue cancer lines with and without corresponding mutations. Front Oncol. 11:6404902021. View Article : Google Scholar : PubMed/NCBI
43	Rihani A, Vandesompele J, Speleman F and Van Maerken T: Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma. Cancer Cell Int. 15:762015. View Article : Google Scholar : PubMed/NCBI
44	Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK and Toogood PL: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 3:1427–1438. 2004. View Article : Google Scholar : PubMed/NCBI
45	Challa S and Kraus WL: Two birds, one stone: Non-canonical therapeutic effects of the PARP inhibitor Talazoparib. Cell Chem Biol. 29:171–173. 2022. View Article : Google Scholar : PubMed/NCBI